ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT

The crizotinib-resistant ALK(F1174L) mutation arises de novo in neuroblastoma (NB) and is acquired in ALK translocation-driven cancers, lending impetus to the development of novel anaplastic lymphoma kinase (ALK) inhibitors with different modes of action. The diaminopyrimidine TAE684 and its derivat...

Descripción completa

Detalles Bibliográficos
Autores principales: Debruyne, D N, Bhatnagar, N, Sharma, B, Luther, W, Moore, N F, Cheung, N-K, Gray, N S, George, R E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885798/
https://www.ncbi.nlm.nih.gov/pubmed/26616860
http://dx.doi.org/10.1038/onc.2015.434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885798/
https://www.ncbi.nlm.nih.gov/pubmed/26616860
http://dx.doi.org/10.1038/onc.2015.434

Ejemplares similares